[HTML][HTML] Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients …
RJ Motzer, CH Barrios, TM Kim, S Falcon… - Journal of Clinical …, 2014 - ncbi.nlm.nih.gov
RJ Motzer, CH Barrios, TM Kim, S Falcon, T Cosgriff, WG Harker, V Srimuninnimit, K Pittman…
Journal of Clinical Oncology, 2014•ncbi.nlm.nih.govPhase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line
Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic
Renal Cell Carcinoma - PMC Back to Top Skip to main content NIH NLM Logo Access keys
NCBI Homepage MyNCBI Homepage Main Content Main Navigation Search PMC Full-Text
Archive Search in PMC Advanced Search User Guide Journal List J Clin Oncol PMC5569681
Other Formats PDF (279K) Actions Cite Collections Share Permalink Copy RESOURCES Similar …
Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic
Renal Cell Carcinoma - PMC Back to Top Skip to main content NIH NLM Logo Access keys
NCBI Homepage MyNCBI Homepage Main Content Main Navigation Search PMC Full-Text
Archive Search in PMC Advanced Search User Guide Journal List J Clin Oncol PMC5569681
Other Formats PDF (279K) Actions Cite Collections Share Permalink Copy RESOURCES Similar …
Abstract
Purpose
A multicenter, randomized phase II trial, RECORD-3, was conducted to compare first-line everolimus followed by sunitinib at progression with the standard sequence of first-line sunitinib followed by everolimus in patients with metastatic renal cell carcinoma.
ncbi.nlm.nih.gov
